Background: An increasing number of cases of Moyamoya disease have been reported in the Japanese and US literature. We performed this study to quantify the rise in the prevalence of Moyamoya disease and to study the unique epidemiological and clinical features in the USA that may explain a change in incidence. Methods: We analyzed data derived from patients entered in the Nationwide Inpatient Sample between 2005 and 2008, using ICD-9 codes for Moyamoya disease. Data including patient age, gender, ethnicity, secondary diagnosis, medical complications, and hospital costs were obtained. Results: From 2005 to 2008 in the USA, there were an estimated 7,473 patients admitted with a primary or secondary diagnosis of Moyamoya disease. Patients admitted with Moyamoya disease were most frequently women and Caucasian. Overall, ischemic stroke was the most common reason for admission. Hemorrhagic stroke was more frequent in adults compared with children, 18.1 versus 1.5% (p < 0.05). Conclusion: The number of patients identified and admitted with Moyamoya disease has risen dramatically in the last decade. This study can lead to a better understanding of the disease pattern and healthcare consequences in the USA and suggests that pathophysiologic differences in Moyamoya disease may exist.

Keywords:
Epidemiology, Moyamoya disease, Ischemic stroke, Intracerebral hemorrhage
1.
Smith E, Scott M: Surgical management of Moyamoya syndrome. Skull Base 2005;15:15-26.
2.
Suzuki J, Kodama N: Moyamoya disease: a review. Stroke 1983;14:104-109.
3.
Fukui M: Current state of study on Moya-moya disease in Japan. Surg Neurol 1997;47:138-143.
4.
Goto Y, Yonekawa Y: Worldwide distribution of moyamoya disease. Neurol Med Chir (Tokyo) 1992;32:883-886.
5.
Kuriyama S, Kusaka Y, Fujimura M, Wakai K, et al: Prevalence and clinicoepidemiological features of Moyamoya disease in Japan. Stroke 2008;39:42-47.
6.
Chui D, Shedden P, Bratina P, Grotta J: Clinical features of Moyamoya disease in the United States. Stroke 1998;29:1347-1351.
7.
Graham JF, Matoba A: A survey of Moyamoya disease in Hawaii. Clin Neurol Neurosurg 1997;99:S31-S35.
8.
Numaguchi Y, Gonzalez CF, Davis PC, et al: Moyamoya disease in the United States. Clin Neurol Neurosurg 1997;99(suppl 2):S26-S30.
9.
HCUP Nationwide Inpatient Sample: Design of the Nationwide Inpatient Sample, 2010.
10.
Ishimori M, Cohen S, Hallegua D, Moser F, Weisman M: Ischemic stroke in a postpartum patient: understanding the epidemiology, pathogenesis, and outcome of Moyamoya disease. Semin Arthritis Rheum 2006;35:250-259.
11.
Yoshida Y, Yoshimoto T, Shirane R, Sakurai Y: Clinical course, surgical management, and long-term outcome of moyamoya patients with rebleeding after an episode of intracerebral hemorrhage: an extensive follow-up study. Stroke 1999;30:2272-2276.
12.
Edwards-Brown MK, Quets J: Midwest experience with Moyamoya disease. Clin Neurol Neurosurg 1997;99:S36-S38.
13.
Scott RM, Smith JL, Robertson RL, et al: Long-term outcome in children with moya-moya syndrome after cranial revascularization by pial synangiosis. J Neurosurg 2004;100(suppl 2):142-149.
14.
Peerless SJ: Risk factors of Moyamoya disease in Canada and the USA. Clin Neurol Neurosurg 1997;99:S45-S48.
15.
Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoiki R, et al: Epidemiologic features of moyamoya disease in Japan: findings from a nationwide survey. Clin Neurol Neurosurg 1997;99:S1-S5.
16.
United States Census Bureau 2010. http://quickfacts.census.gov.
17.
Zipel G, Fox D, Rivet D: Moyamoya Disease in adults: the role of cerebral vascularization. Skull Base 2005;15:27-41.
18.
Lee D, Liebeskind D: Characterization of inpatient moyamoya in the United States: 1988-2004. Front Neurol 2011;2:1-5.
19.
Ikezaki K, Han DH, Kawano T, Kinuwaka N, Fukui M: A clinical comparison of definite moyamoya disease between South Korea and Japan. Stroke 1997;28:2513-2517.
20.
Yilmaz E, Pritz M, Bruno A, et al: Moyamoya: Indiana University Medical Center experience. Arch Neurol 2001;58:1274-1278.
21.
Yamashita M, Oka K, Tanaka K: Histopathology of the brain vascular network in moyamoya disease. Stroke 1983;14:50-58.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.